Assessing environmental impact of medicines financially ‘catastrophic’ for pharmaceutical industry
Assessing the environmental risks of a new medicine as part of the risk-benefit assessment during market authorisation would be “catastrophic” for the pharmaceutical industry, an environmental scientist from manufacturer AstraZeneca has said.…